kpti

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) together with the Multiple Myeloma Research Foundation (MMRF) announced that Karyopharm will host an investor and analyst dinner reception featuring a panel discussion with recognized multiple myeloma (MM) thought leaders and moderated by Daniel Auclair, PhD,┬áSenior Vice President of Research at the MMRF. The Karyopharm-sponsored event is scheduled for Monday, December 5, 2016 from 8:15 – 9:30 p.m. PT, immediately following formal programming for the 58th American Society of Hematology (ASH) Annual Meeting.

“Despite recent advances that have substantially improved the life expectancy of myeloma patients, a cure remains elusive and treatment gaps persist,” said Dr. Auclair. “We are encouraged by the growing body of research to suggest that oral selinexor, alone and in combination with other approved therapies, represents a potential breakthrough in the treatment of multi-refractory myeloma patients, where a high unmet medical need still exists.” (Original Source)

Shares of Karyopharm closed yesterday at $9.30 up $0.01 or 0.11%. KPTI has a 1-year high of $18.11 and a 1-year low of $4.83. The stock’s 50-day moving average is $8.81 and its 200-day moving average is $8.28.

On the ratings front, Karyopharm has been the subject of a number of recent research reports. In a report issued on November 8, JMP analyst Michael King reiterated a Buy rating on KPTI. Separately, on the same day, H.C. Wainwright’s Shaunak Deepak reiterated a Buy rating on the stock and has a price target of $15.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Michael King and Shaunak Deepak have a yearly average return of 1.2% and a loss of 17.1% respectively. King has a success rate of 46% and is ranked #1834 out of 4241 analysts, while Deepak has a success rate of 41% and is ranked #4025.

Sentiment on the Street is mostly bullish on KPTI stock. Out of 7 analysts who cover the stock, 7 suggest a Buy rating. The 12-month average price target assigned to the stock is $18.00, which implies an upside of 94% from current levels.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Its selective inhibitors of nuclear export compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.